**5. Conclusions**

Stroke is a major concern in patients undergoing TAVR that can affect mortality and morbidity. TAVR expanding indication to low risk young patients raises issues on prevent or reduce the incidence of cerebrovascular ischaemic events that could be pursued through embolic protection devices. Clear univocal evidence does not support the routine use of cerebral embolic protection devices during TAVR to prevent stroke and improve outcomes. However, it may be useful in patients judged at high risk of neurological events; further studies about the ideal patient selection are warranted.
